PANELS Below are the synopses of the conference panel discussions. Please check back regularly as updates will be made on a daily basis. Emerging Revolutions in Bioscience Moderator: Panelists: William Kridel Ferghana Partners Abbie Celniker, Ph.D. Novartis Jeremy Goldberg Endo Pharmaceuticals Manuel A. Navia Oxford Bioscience Partners Steve Projan Wyeth Frederic J. Vinick, Ph.D. Genzyme Corporation The aging population and rising pharmaceutical costs demand drug makers to deliver products to patients in an efficient and effective manner. Breakthroughs in medical science and technology offer a myriad of opportunities to identify new drug targets and to accelerate the drug R&D process. Pharmaceutical and biotech companies are facing the challenge of developing innovative therapies to address unmet medical needs while maintaining access and affordability. Some of the questions this panel will address include: What models do pharmaceutical and biotech companies use to drive innovation? What are the novel approaches used to accelerate drug research and development processes? What criteria are being used to evaluate internal pipeline and external drug targets? How do you allocate financial resources between these two sources? How do you balance innovation with access and affordability? How will existing and new players in the Biosciences industry work together going forward? Emerging Trends in Healthcare Delivery Moderator: Panelists: Andrew Vaz Deloitte Consulting Allan Goroll, MD Jon Kingsdale Commonwealth Health Insurance Connector Authority Robert Mandel, MD, MBA　 With healthcare expenses accounting for 15% and rising of the US GDP, trends and changes in the payor/provider sector impact all of us: as consumers, future healthcare professionals, and business leaders. Yet innovation within healthcare delivery is notoriously difficult. In this panel, a distinguished group of experts from clinical practice, insurance, consulting and academia explores several emerging solutions: How are trends such as pay-for-performance and universal coverage fueling innovation in the sector What new models are established and entrepreneurial firms using to capture and create value while serving patients' needs? What lessons does Massachusetts experiment in universal healthcare offer the rest of the nation? How will current and upcoming changes in payment policies impact us as individuals and business leaders? What obstacles and opportunities exist on the horizon for business professionals entering this sector? Life Cycle of a Biotech Company: Evolving Drug Development, Funding and Exit Strategies Moderator: Panelists: Robert F. Higgins Highland Capital Joshua Boger, Ph.D. Vertex Pharmaceuticals John Dee Hypnion Inc. Nicholas Galakatos Ph.D. Clarus Ventures Ed Scolnick, MD Merck Research 　 The cash intensive nature of the drug business has forced Biotech companies to regularly adapt their business models as their funding and exit requirements change. In the recent years, IPO criteria have become even tougher; to secure reasonable valuation often requires a Phase 2 or later clinical program and a pipeline. A number of high value Pharma acquisitions has also demonstrated M&A as a very competitive alternative exit option. It appears that companies today must raise more funding than before prior to exiting. We believe that these factors conspired to push VC’s toward funding compounds and not technologies, and companies in turn have become conservative with their R&D. From our panelists, we’d like to understand how they view the current funding environment and explore this impact on innovation. Some of the issues include: Where are biotechs getting assets and at what cost? Is there a funding gap in turning good science into good drugs? How are companies dealing with the increased financing needs and is its impact on innovation? What are VC’s doing about this gap? How are the relationships evolving between biotechs, investors and big pharma throughout a company’s life cycle? Are there ways to fund earlier, more exploratory programs outside of Pharma, or have the biotechs only remade themselves into mini-pharma’s? How are exit strategies evolving for biotechs? What are the pros/cons of various strategies? Medical Device Innovation: What’s hot? Who’s driving innovation? Where is the industry heading? Moderator: Panelists: Ken Hutt Deloitte Consulting Leon Amariglio Rhythmia Medical Dr. David Israeli Medtronic Terry McGuire Polaris Venture Partners Aaron Sandoski Norwich Ventures John Sheets, Ph.D Ethicon (a J&J subsidiary) As with other areas of healthcare, the medical device industry has been a hotbed of innovation focusing on a variety of technologies ranging from improving diagnostics to creating patient self-monitoring tools. This panel will discuss the forces that are driving change and innovation as well as some of the latest developments in the medical device industry. The panelists represent different industry players including start-ups, large established companies and venture capitalists, and they will address the following questions: What are most cutting-edge developments within medical devices? How are sub-industries (implantable devices w/drug delivery, monitoring and delivery, nanotechnology, etc.) working together to innovate? What role do early-stage companies play in medical device innovation? What are the current and future challenges of the medical device industry? Commercializing Stem Cell Research: The Potential, the Challenges and the Future Moderator: Panelists: Deborah Spar Harvard Business School Marc Beer ViaCell Bruce Booth Atlas Venture Dan Marshak PerkinElmer, Inc. Brock Reeve Harvard Stem Cell Institute William Sahlmann Harvard Business School 　 This panel will explore the current trends in science, ethics, investing, and public policy associated with stem cell research. The panel will focus on which stem cell business models will succeed and what it will take to bring a stem cell therapy from the lab to marketplace. Topics will include technologies and products that have been developed and/or are currently available in regenerative medicine; the potential for new products; whether viable alternatives exist for embryonic stem cells in developing new technologies; the political considerations that went into drafting and proposing Federal and State legislation for expanding funding for embryonic stem cell lines; sources of private funding and other considerations of companies that pursue regenerative medicine; and the potential for losing technology and business to Europe and other locations with less restrictive policies regarding stem cell research The following issues will be explored: What are the technologies and products available in regenerative medicine? What is the potential for new products using stem cells? 　 Who is funding stem cell research? 　 How are regulations in the US and internationally impacting stem cell research? 　 Life after the MBA in Healthcare Moderator: Panelists: Rahul Mehendale Deloitte Consulting Bill Fruhan Boston Scientific Ian Mclean Bristol Myers Squibb Company Sarah Mullen Caritas St. Elizabeth's Medical Center Sara Nayeem Harvard Business School Rachel Sha Genzyme 　 Students often have visions of the type of impact they want to have and where they want to be when they grow up, but are at times confused about what that means coming right out of school.  Defining a clear short-term career path is critical to establishing a strong foundation of skills and contacts to enable people to reach the positions they strive for in the long-term. To help students and young industry professionals, this panel will explore questions such as: What areas of healthcare or positions within an organization are particularly receptive to MBAs? How should one think about the short-term career path? What advice has been helpful in looking for summer internships, full-time job searches and in thinking about careers within the first 5 years?	Saturday, December 2, 2006
2005 sitee © 2006 HBS Healthcare Club Conference, All Rights Reserved.